Oculis has completed the final patient visit in both Phase 3 DIAMOND trials evaluating OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology, in diabetic macular edema. Topline data from the two 52‑week, double‑masked, randomized, multicenter studies, which enrolled more than 800 patients, are expected in June 2026, with a potential U.S. filing targeted for the fourth quarter. The primary endpoint is change in best corrected visual acuity at Week 52, with key secondary measures including ≥15‑letter gains and reduction in central subfield thickness.
If positive, this could be the first topical therapy for a retinal disease that has long been dominated by intravitreal injections, and it would challenge entrenched clinical workflows and economic models. The strategic question is not only whether OCS‑01 can deliver clinically meaningful, durable vision gains, but whether a six‑times‑daily induction and three‑times‑daily maintenance dosing regimen can overcome adherence hurdles and still generate payer and HCP confidence at scale.
The timing matters. Despite an expanding anti‑VEGF toolkit and steroid implants, DME remains under‑treated and variably responsive. Real‑world data suggest roughly 60% of newly diagnosed patients in the U.S. remain untreated one year after diagnosis, and about 40% of those treated have sub‑optimal response to current standards. A non‑invasive, pharmacy‑dispensed option could open earlier intervention in patients with mild visual loss who are commonly observed, while offering an adjunct for inadequate responders. That dynamic does more than shift share within a roughly $3 billion U.S. market; it potentially enlarges it by activating a large pool of untreated or undertreated patients.
Commercially, a topical introduces new leverage points with payers and providers. For mild to moderate disease, a lower-cost drop could become a preferred first step before higher-cost injections, especially under pharmacy benefit management. That would pressure buy‑and‑bill economics in retina practices and could reconfigure step‑therapy algorithms that today often start with bevacizumab. Success would depend on demonstrating meaningful visual gains, durability through 52 weeks, and pragmatic adherence. Steroid‑class safety remains pivotal: any signal on intraocular pressure or cataract formation will influence monitoring requirements, cost offsets, and ultimate positioning as monotherapy or combination therapy.
For Medical Affairs, the path to adoption will hinge on targeted education around DME phenotypes more likely to respond to steroid‑mediated anti‑inflammatory effects, practical IOP monitoring protocols, and real‑world adherence support during the intensive induction phase. Robust post‑approval evidence—by line of therapy, baseline vision, edema chronicity, and prior anti‑VEGF exposure—will be necessary to anchor formulary decisions and guideline updates. Digital adherence tools and coordinated care with endocrinology and primary care offer an avenue to capture earlier-stage patients who rarely reach retina clinics in time.
The move also fits a broader shift in ophthalmology toward less invasive, more durable, and more convenient modalities. While long‑acting anti‑VEGFs, sustained‑delivery steroids, and gene therapy aim to reduce injection frequency, OCS‑01 tests whether topical delivery can reach the posterior segment with clinically relevant effect. If the DIAMOND readout confirms the Stage 1 signal of rapid edema reduction and vision improvement, expect renewed M&A interest in posterior‑segment topical technologies and a competitive response from incumbents seeking to defend injection franchises.
June’s topline will need to answer three questions decisively: Is the visual acuity delta large and consistent across subgroups, is the safety profile manageable without onerous monitoring, and can real‑world adherence sustain the dosing intensity? If the answers are yes, payers may recast early DME management around a pharmacy‑benefit topical, shifting power from procedure‑centric care to prescription‑driven pathways—and forcing competitors to rethink how value is delivered, measured, and paid for in retinal disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
